IGC Pharma Secures Analyst Upgrade to $5.50 on Alzheimer's Research Advancements

New York, Tuesday, 9 June 2026.
Driven by promising Phase 2 Alzheimer’s trial progress, Ascendiant Capital Markets raised IGC Pharma’s price target to $5.50 today, signaling strong confidence in the company’s 2026 clinical pipeline.